72152-84-2

Usage

Uses

Used in Pharmaceutical Industry:
2,6,6-Trimethylcyclohexa-1,3-dien-1-ylcarbonitrile is used as a therapeutic agent for treating ocular diseases associated with increased all-trans retinal in ocular tissue. Its application is based on its ability to address the underlying cause of the disease by targeting and managing the levels of all-trans retinal, which is crucial for maintaining healthy ocular function.

InChI:InChI=1/C10H13N/c1-8-5-4-6-10(2,3)9(8)7-11/h4-5H,6H2,1-3H3

Upstream product

• 57524-14-8 2,2,6-trimethyl-1-cyclohexenylcarbonitrile 
• 145106-79-2 3-hydroxy-2,6,6-trimethylcyclohex-1-enecarbonitrile 
• 145106-80-5 2,6,6-Trimethyl-3-bromocyclohex-1-ene-1-carbonitrile 
• 108-24-7 acetic anhydride 
• 57524-13-7 2,6,6-trimethyl-2-cyclohexenecarbonitrile 
• 264279-20-1 2,3-epoxy-2,6,6-trimethyl-1-cyclohexanecarbonitrile 
• 2408-37-9 2,2,6-trimethylcyclohexan-1-one 
• 56830-39-8 2,4,4-Trimethylcyclohex-2-en-1-one-3-carbonitrile 
• 103324-66-9 1-hydroxy-2,2,6-trimethyl-cyclohexanecarbonitrile 
• 73661-48-0 oxime 2,6,6-trimethylcyclohex-1-ene-1-carbaldehyde 
• 110-93-0 6-Methyl-hept-5-en-2-on 
• 5585-39-7 (E)-3,7-dimethylocta-2,6-dienenitrile 
• 5146-66-7 geranonitrile 
• 145106-55-4 (1S,2R,5S) 1-(1-Methylethyl)-2,4,4-trimethylbicyclo<3.1.0>hexan-3-one 

Downstream Products

• 35044-69-0 2-Allyl-2,6,6-trimethyl-cyclohex-3-enecarbonitrile 
• 35044-70-3 4-Allyl-2,6,6-trimethyl-cyclohex-2-enecarbonitrile 
• 116-26-7 safranal 
• 42926-75-0 2,6,6-trimethyl-4-hydroxy-1-cyclohexene-1-carboxaldehyde 
• 23726-93-4 Damascenon 
• 78182-05-5 (E)-1-(2,6,6-Trimethylcyclohexa-1,3-dienyl)but-2-en-1-ol 
• 6890-91-1 (3RS,all-E)-hydroxyretinal 
• 7584-74-9 C₂₀H₂₈O₂ 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS

A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I); and pharmaceutically acceptable salts thereof.

Expansion of first-in-class drug candidates that sequester toxic all-trans-retinal and prevent light-induced retinal degeneration

All-trans-retinal, a retinoid metabolite naturally produced upon photoreceptor light activation, is cytotoxic when present at elevated levels in the retina. To lower its toxicity, two experimentally validated methods have been developed involving inhibition of the retinoid cycle and sequestration of excess of all-trans-retinal by drugs containing a primary amine group. We identified the first-in-class drug candidates that transiently sequester this metabolite or slow down its production by inhibiting regeneration of the visual chromophore, 11-cis-retinal. Two enzymes are critical for retinoid recycling in the eye. Lecithin:retinol acyltransferase (LRAT) is the enzyme that traps vitamin A (all-trans-retinol) from the circulation and photoreceptor cells to produce the esterified substrate for retinoid isomerase (RPE65), which converts all-trans-retinyl ester into 11-cis-retinol. Here we investigated retinylamine and its derivatives to assess their inhibitor/substrate specificities for RPE65 and LRAT, mechanisms of action, potency, retention in the eye, and protection against acute light-induced retinal degeneration in mice. We correlated levels of visual cycle inhibition with retinal protective effects and outlined chemical boundaries for LRAT substrates and RPE65 inhibitors to obtain critical insights into therapeutic properties needed for retinal preservation.

Synthetic scheme for the preparation of 13C-labeled 3,4-didehydro-retinal, 3-hydroxyretinal, and 4-hydroxyretinal up to uniform 13C-enrichment

A modular synthetic scheme has been developed for the synthesis of 13C-labeled naturally occurring visual pigment chromophores; 3,4-didehydroretinal, 3-hydroxyretinal, and 4-hydroxyretinal. These compounds can now be made with > 99% 13C enrichment at any position or combination of positions. We used the common C10+C5+C5 scheme for the synthesis of retinals, and by making variations in the C10 part we can now prepare the desired retinal derivatives with selective or uniform 13C enrichment. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.

The chemistry of thujone. XVI. Versatile and efficient routes to safronitrile, β-cyclogeranonitrile, β-cyclocitral, damascones, and their analogues

Thujone, a waste by-product of the Canadian forest industry, has been utilized as a starting material to develop a versatile synthetic route to the damascones (rose oil ketones) and related analogues.The synthetic sequence provides a route to β-cyclocitral (45), the latter having been previously converted to β-damascone (2).In addition, thujone-drived intermediates are converted to β-damascenone (48) and to intermediates that can be utilized for the preparation of damascone analogues.In conjunction with the above, an efficient route to safronitrile (42), β-cyclogeranonitrile (43), and β-cyclocitral (45) from 2,6-dimethylcyclohexanone has been developed.In summary, these studies afford an attractive versatile route to these important perfumery materials.